Coronary/Structural Heart

Humacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Vessel™ to Treat Wartime Vascular Trauma at the European Society for Vascular Surgery Annual Meeting

HAV™ was utilized to treat multiple patients suffering from shrapnel, gunshot wounds, and mine blast injuries DURHAM, N.C., Sept. 23, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues, complex tissue systems, and organs at commercial scale, today announced the presentation […]

Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial

Study Was Evaluating the Use of Apixaban in Patients Treated with Mechanical Aortic Valves ATLANTA, Sept. 23, 2022 /PRNewswire/ — Artivion, Inc. ( NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has stopped the PROACT Xa clinical trial, a prospective, randomized, trial designed to determine if […]

Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia

ION449 (AZD8233) met primary endpoint in Phase 2b SOLANO study for patients with hypercholesterolemia ION449 will not advance into Phase 3 development based on pre-specified criteria CARLSBAD, Calif., Sept. 23, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. ( Nasdaq: IONS) today announced that topline results from the Phase 2b SOLANO study in patients with hypercholesterolemia demonstrated that 60mg of ION449 (AZD8233) […]

TCT2022| Pulnovo Medical Announced That The Latest Results Of PADN-CFDA Pivotal Trial Indicate Effectiveness And Safety of PADN For The Treatment Of Pulmonary Arterial Hypertension (PAH)

SHANGHAI, Sept. 23, 2022 /PRNewswire/ — Pulnovo Medical Limited, a globally recognized OTM platform, today announced the positive results from the Pulmonary Artery Denervation (PADN)-CFDA pivotal study on the world’s largest and most influential American transcatheter cardiovascular therapy conference (TCT 2022). PADN is an innovative radiofrequency ablation technique in treating PH, […]

FDA Clears DyAnsys Neurostimulation Device Primary Relief to Treat Post-Cardiac Surgery Pain

PALO ALTO, Calif., Sept. 22, 2022 /PRNewswire/ — DyAnsys, Inc., has announced that Primary Relief, a percutaneous electrical neurostimulation device, has been approved to treat pain following a cardiac surgery. The percutaneous electrical nerve stimulator (PENS) system can be used for up to three days for symptomatic relief of post-operative pain following […]

Vicore announces that C21 promotes vascular function in humans

Clinically relevant doses of C21 increase blood flow in humans Systemic blood pressure was unaffected, and no side effects were observed The forearm blood flow method is a robust technique for early clinical concept testing GOTHENBURG, Sweden, Sept. 22, 2022 /PRNewswire/ —  Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing […]

New Study Published in an American Heart Association Journal Indicates that Hello Heart’s Digital Coaching App Could Contribute to Heart Health Equity

The findings were published in the American Heart Association’s Hypertension journal and showed consistency of program results across diverse populations. MENLO PARK, Calif.–(BUSINESS WIRE)–Hello Heart, the only digital therapeutic that focuses exclusively on heart health, has released a new study evaluating the program’s results for various user population groups in order to demonstrate […]

Cardio Diagnostics Announces Issuance of U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease

CHICAGO, Sept. 21, 2022 /PRNewswire/ — Cardio Diagnostics, Inc. (“Cardio Diagnostics” or the “Company”), a pioneering precision cardiovascular testing company, today announced that the U.S. Patent and Trademark Office has issued to the University of Iowa Research Foundation (“UIRF”) U.S. Patent No. 11,414,704 titled COMPOSITIONS AND METHODS FOR DETECTING PREDISPOSITION TO CARDIOVASCULAR DISEASE, which is exclusively […]

Verve Therapeutics Announces Clearance of Clinical Trial Authorisation Application by the United Kingdom Medicines and Healthcare Products Regulatory Agency for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia

CAMBRIDGE, Mass., Sept. 21, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the clearance of its Clinical Trial Authorisation (CTA) application by the United Kingdom (U.K.) Medicines and Healthcare products Regulatory […]

Getinge partners with Medtronic for the manufacturing of the Radiant[TM] balloon-expandable covered stent

Getinge announces a supply partnership with Medtronic, which recently received CE mark for the Radiant™ covered stent, the first covered stent indicated for chimney endovascular aneurysm repair (ChEVAR). The Radiant covered stent is a private labeled Advanta V12 balloon expandable covered stent produced by Getinge and distributed by Medtronic. The […]